Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

111.05 -0.10 (-0.09%)
Streaming Delayed Price Updated: 12:01 PM EDT, Aug 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Merck to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END 
Via FinancialNewsMedia
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and... 
Via FinancialNewsMedia
Exposures COVID-19
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
From Merck & Co., Inc.
Via Business Wire
Why Investors Are Suddenly Excited About Vaxcyte
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet. 
Via MarketBeat
Exposures COVID-19
Can Big Data Make Patient Care More Personalized And Effective?
It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets... 
Via TheNewswire.com
Merck Stock Price Rose as the Company Raised Its Full-Year Outlook Due to the Success of Keytruda
Merck & Co Inc (NYSE:MRK) A rise in demand for blockbuster cancer treatment Keytruda and human papillomavirus vaccination Gardasil contributed to Merck & Co Inc (NYSE: MRK) higher-than-expected sales... 
Via PressReach
Topics Intellectual Property
Exposures Intellectual Property
Merck Beats Expectations for the Third Quarter as Sales of the COVID-19 Tablet Are Partially Offset by Keytruda
Merck stock was trading at $100.91 as of 09:49 AM EDT. After reporting stronger-than-anticipated financial results for the third quarter of 2022, Merck (NYSE:MRK) saw its pre-market trading price... 
Via PressReach
Exposures COVID-19
Merck Announces Third-Quarter 2022 Financial Results
From Merck & Co., Inc.
Via Business Wire
Eli Lilly Dividend: Does Eli Lilly Pay Dividends?
Yes, Eli Lilly and Company (NYSE: LLY) pays dividends but there is more to investing in this stock than a simple “yes” answer. The Eli Lilly dividend is safe enough but it may not be right for all... 
Via MarketBeat
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
From Merck & Co., Inc.
Via Business Wire
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
From Merck & Co., Inc.
Via Business Wire
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
From Merck & Co., Inc.
Via Business Wire
MarketBeat: Week in Review 10/17-10/21
Stocks are staging a rally to end the week. But economic data next week may bring more volatility. Here are some of the most popular articles from this week 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
From Merck & Co., Inc.
Via Business Wire
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
From Merck & Co., Inc.
Via Business Wire
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc.
Via Business Wire
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
From Merck & Co., Inc.
Via Business Wire
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Merck Animal Health to Acquire Vence
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
From Merck & Co., Inc. Merck
Via Business Wire
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
18 19 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.